Based on the key indicators related to IGM Biosciences' liquidity, profitability, solvency, and operating efficiency, IGM Biosciences is not in a good financial situation at this time. It has a very high odds of going through financial crisis in December. At this time, IGM Biosciences' Other Stockholder Equity is comparatively stable compared to the past year. Total Liabilities is likely to gain to about 231.2 M in 2024, whereas Total Current Liabilities is likely to drop slightly above 23.7 M in 2024. Key indicators impacting IGM Biosciences' financial strength include:
The financial analysis of IGM Biosciences is a critical element in measuring its lifeblood. Investors should not minimize IGM Biosciences' ability to pay suppliers or employees on time, ensuring interest payments are not accumulating.
Net Income
(234.1 Million)
IGM
Select Account or Indicator
Market Cap
Enterprise Value
Ptb Ratio
Book Value Per Share
Free Cash Flow Yield
Operating Cash Flow Per Share
Capex To Depreciation
Pb Ratio
Free Cash Flow Per Share
Roic
Net Income Per Share
Payables Turnover
Cash Per Share
Pocfratio
Capex To Operating Cash Flow
Pfcf Ratio
Days Payables Outstanding
Income Quality
Roe
Ev To Operating Cash Flow
Pe Ratio
Return On Tangible Assets
Ev To Free Cash Flow
Earnings Yield
Net Debt To E B I T D A
Current Ratio
Tangible Book Value Per Share
Graham Number
Shareholders Equity Per Share
Debt To Equity
Capex Per Share
Graham Net Net
Interest Debt Per Share
Debt To Assets
Enterprise Value Over E B I T D A
Short Term Coverage Ratios
Price Earnings Ratio
Price Book Value Ratio
Price Earnings To Growth Ratio
Days Of Payables Outstanding
Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio
Ebt Per Ebit
Effective Tax Rate
Company Equity Multiplier
Total Debt To Capitalization
Return On Capital Employed
Debt Equity Ratio
Quick Ratio
Dividend Paid And Capex Coverage Ratio
Cash Ratio
Free Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage Ratios
Price To Book Ratio
Capital Expenditure Coverage Ratio
Price Cash Flow Ratio
Enterprise Value Multiple
Debt Ratio
Cash Flow To Debt Ratio
Return On Assets
Price Fair Value
Return On Equity
Sale Purchase Of Stock
Investments
Change In Cash
Net Borrowings
Stock Based Compensation
Free Cash Flow
Change In Working Capital
Begin Period Cash Flow
Total Cashflows From Investing Activities
Other Cashflows From Financing Activities
Depreciation
Capital Expenditures
Cash And Cash Equivalents Changes
Total Cash From Operating Activities
Cash Flows Other Operating
Change To Operating Activities
Net Income
Total Cash From Financing Activities
End Period Cash Flow
Change To Netincome
Change To Liabilities
Other Non Cash Items
Issuance Of Capital Stock
Total Assets
Other Current Liab
Total Current Liabilities
Total Stockholder Equity
Other Liab
Net Tangible Assets
Property Plant And Equipment Net
Net Debt
Retained Earnings
Accounts Payable
Cash
Non Current Assets Total
Non Currrent Assets Other
Other Assets
Cash And Short Term Investments
Common Stock Total Equity
Retained Earnings Total Equity
Common Stock Shares Outstanding
Short Term Investments
Liabilities And Stockholders Equity
Non Current Liabilities Total
Capital Surpluse
Capital Lease Obligations
Other Current Assets
Other Stockholder Equity
Total Liab
Net Invested Capital
Property Plant And Equipment Gross
Total Current Assets
Accumulated Other Comprehensive Income
Non Current Liabilities Other
Net Working Capital
Short Term Debt
Common Stock
Property Plant Equipment
Short Long Term Debt Total
Capital Stock
Depreciation And Amortization
Interest Expense
Selling General Administrative
Total Revenue
Gross Profit
Other Operating Expenses
Operating Income
Net Income From Continuing Ops
Ebit
Research Development
Ebitda
Cost Of Revenue
Total Operating Expenses
Reconciled Depreciation
Income Before Tax
Non Operating Income Net Other
Total Other Income Expense Net
Net Income Applicable To Common Shares
Income Tax Expense
Net Interest Income
Interest Income
Probability Of Bankruptcy
Understanding current and past IGM Biosciences Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of IGM Biosciences' financial statements are interrelated, with each one affecting the others. For example, an increase in IGM Biosciences' assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in IGM Biosciences' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of IGM Biosciences. Check IGM Biosciences' Beneish M Score to see the likelihood of IGM Biosciences' management manipulating its earnings.
IGM Biosciences Stock Summary
IGM Biosciences competes with Avidity Biosciences, Cullinan Oncology, Mineralys Therapeutics,, Monte Rosa, and Design Therapeutics. IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California. Igm Biosciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 242 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
Comparative valuation techniques use various fundamental indicators to help in determining IGM Biosciences's current stock value. Our valuation model uses many indicators to compare IGM Biosciences value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across IGM Biosciences competition to find correlations between indicators driving IGM Biosciences's intrinsic value. More Info.
IGM Biosciences is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, IGM Biosciences' Return On Equity is comparatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value IGM Biosciences by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.
IGM Biosciences Systematic Risk
IGM Biosciences' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. IGM Biosciences volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was thirty-six with a total number of output elements of twenty-five. The Beta measures systematic risk based on how returns on IGM Biosciences correlated with the market. If Beta is less than 0 IGM Biosciences generally moves in the opposite direction as compared to the market. If IGM Biosciences Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one IGM Biosciences is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of IGM Biosciences is generally in the same direction as the market. If Beta > 1 IGM Biosciences moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in IGM Biosciences Stock are looking for potential investment opportunities by analyzing not only static indicators but also various IGM Biosciences' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of IGM Biosciences growth as a starting point in their analysis.
IGM Biosciences November 22, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of IGM Biosciences help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of IGM Biosciences. We use our internally-developed statistical techniques to arrive at the intrinsic value of IGM Biosciences based on widely used predictive technical indicators. In general, we focus on analyzing IGM Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build IGM Biosciences's daily price indicators and compare them against related drivers.
When running IGM Biosciences' price analysis, check to measure IGM Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy IGM Biosciences is operating at the current time. Most of IGM Biosciences' value examination focuses on studying past and present price action to predict the probability of IGM Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move IGM Biosciences' price. Additionally, you may evaluate how the addition of IGM Biosciences to your portfolios can decrease your overall portfolio volatility.